Sawai Pharma Moves Up Launch Dates For Generics to Beat Competitors
This article was originally published in PharmAsia News
Sawai Pharmaceutical plans an earlier-than-planned launch of several generic drugs in a race to reach the market ahead of competitors.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.